Eric Gulve, PhD. joined BioGenerator in 2007 following a 14 year career in the pharmaceutical industry. In 2009 he assumed overall leadership of BioGenerator. His responsibilities have expanded to include overall strategic direction, expansion of programs and services, oversight of the organizational budget, community outreach, regional collaborations, and service on the Board of Directors of several BioGenerator portfolio companies.
Prior to joining BioGenerator, Eric spent 14 years in the pharmaceutical industry focused on drug discovery research. From 2003 – 2007 he held various roles in local and global leadership teams in Cardiovascular research at Pfizer, and led laboratories working in the areas of thrombosis, hypertension, and metabolic disease. From 2000 – 2003, Eric was Associate Director of the Cardiovascular & Metabolic Diseases research group at Pharmacia Corporation, prior to Pharmacia's acquisition by Pfizer. From 1994 – 2000 he directed laboratory groups and served on leadership teams within G.D. Searle's Cardiovascular drug discovery research group, where he established the company's first diabetes research program. In addition to laboratory oversight and roles on therapeutic area discovery research leadership teams, Eric held other leadership roles, e.g. on drug discovery teams and new drug target identification/validation teams. In all three companies he held various roles on cardiovascular and metabolic disease therapeutic area in-licensing teams. Eric has worked collaboratively across different research lines, therapeutics areas, business units, and geographic sites. Over the course of his career he has supervised or mentored Ph.D., M.S. and B.A. scientists working inside and outside of his laboratories.
Eric received an A.B. in Chemistry from Occidental College (Los Angeles) and a Ph.D. in Physiology from Harvard University. He served as post-doctoral fellow and research faculty at Washington University School of Medicine, where his research focused on skeletal muscle metabolism and the molecular mechanisms which contribute to the beneficial effects of exercise in diabetes and other states characterized by defective glucose metabolism. He has worked directly or overseen the work of direct reports in a number of different fields including skeletal muscle carbohydrate and protein metabolism, diabetes, thrombosis, and hypertension. Eric has published over 40 peer-reviewed articles and has contributed to several book chapters and review articles. He continues to lecture periodically on the subjects of skeletal muscle metabolism, diabetes, and muscle protein turnover.
Dan Broderick has over 22 years of experience in the life sciences and venture capital industry. Prior to joining Prolog Ventures in 2007, Dan spent 7 years with Mason Wells Biomedical Fund as a Managing Director where he was responsible for all aspects of investment activities. While at Mason Wells, Dan served as a member of the Board of Directors of several portfolio companies including Gala Biotech, Mezzia, OpGen, Deltanoid Pharmaceuticals and ZyStor Therapeutics.
Prior to Mason Wells, Dan spent 18 years at Mayo Clinic in Rochester, Minnesota, where for 12 years he served as Director of the Office of Technology Commercialization. He has personally evaluated the commercial potential of hundreds of technologies in virtually every medical specialty. He has been directly responsible for negotiating and consummating over 100 medical technology commercialization agreements. He has experience with technology evaluation, market assessment, negotiations, academic institution technology transfer, and intellectual property management.
Dan played a key role in the launch of Mayo Clinic’s $25 million venture investing program. He co-founded and served on the Board of Directors of IntraTherapuetics, Inc., CNSoftware, and Medintell, Inc. In 1994, Dan was honored with an appointment to the Staff of Mayo Clinic.
Dan is actively involved in the venture capital community on a regional and national level. He served on the Board of Directors of the National Venture Capital Association (NVCA). He has testified before the U.S. Congress on behalf of the NVCA; works on a number of NVCA committees, and Chaired the Research Committee. Dan is the founder of the Mid-America Healthcare Investor Network (MHIN) and currently serves as President of the organization. He also is the past President of the Wisconsin Biotechnology and Medical Device Association, sat on the Advisory Boards of the University of Minnesota’s Office of Business Development, and BioGenerator in St. Louis, Missouri. He also served as a member of the Board of Trustees for the Medical College of Wisconsin Research Foundation and the University of Wisconsin – Milwaukee Research Foundation.
Dan received a Bachelors Degree in Biology from Iowa State University in 1982. He has completed some graduate course work in Finance, Accounting, and Marketing at Winona State University.
Charlie Bolten was recruited to BioGenerator in July of 2009.
Charlie participates in all aspects of technology commercialization at BioGenerator. His specific responsibilities include the BioGenerator Spark Fund and BioGenerator Accelerator Labs programs, which he conceived of and directs. Charlie serves as the Commercialization Director of the St. Louis Regional i6 Project where he chairs the Project Core Team and leads all investment activity.
Since joining BioGenerator in 2009, Charlie has led 19 investments in 15 portfolio companies, typically participating in formation of the company and/or leading the first investment syndicate. Example portfolio companies include Confluence Life Sciences, Apse, Kypha, X-tend Energy, MediBeacon, Euclises and Array Bridge. Charlie serves on the Board of Directors for various portfolio companies.
At the time of his recruitment to BioGenerator, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology collaboration with PTC Therapeutics focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor.
Edward Hamati has over 11 years of experience in finance, business strategy, management consulting and laboratory research roles. He joined BioGenerator in 2012 to focus on due diligence activities with an emphasis on the seed fund side. Additionally, Edward provides strategic advisory services to current and potential portfolio companies and opportunities as they enter the due diligence process.
Before joining BioGenerator, Edward served at The Chi Rho Group, a private equity firm that functioned as the family investment arm of the Steward family, owners of World Wide Technology Inc. Edward was responsible for review of new M&A opportunities, due diligence, government initiatives, and oversight of the existing investment portfolio. He also oversaw special projects, including a Fortune 500 business intelligence initiative, a turnaround strategy for a consumer packaged goods firm, a health care supply chain initiative for the federal government, and development of an implementation plan for a Fortune 500 scale fulfillment firm.
Prior to his role at the Chi Rho Group, Edward worked for The Broadband Group, a management consulting firm focused on the telecom industry. Edward founded the financial services platform for the company including the development of several proprietary financial models. He was also responsible for drafting business plans and raising equity and debt financing to fund new telecom entities, startups and business development initiatives. Additionally, he represented several Fortune 500 companies including large OEM players Hitachi Telecom and Alcatel Lucent.
Earlier in his career, Edward worked at the Center for Comparative Respiratory Biology and Medicine at UC Davis as a laboratory manager and scientist. Research areas included analysis of viral infections on gene expression, tobacco smoke research, and various mucus secretion pathways, all within human and animal models. Edward is a coauthor on several publications in Respiratory Medicine.
Edward has a BS in Cellular Biology from University of California, Davis. He earned his MBA from California State University, Sacramento in Finance and Business Strategy and attended University of Oxford, United Kingdom as an attachment to his MBA with a focus in business strategy. He also attended the Sacramento Entrepreneurship Academy, further enhancing his knowledge and experience in providing due diligence, business plan development and corporate start-up models.
Eric joined the BioGenerator in 2013 and brings over 12 years of scientific research, pharmaceutical consulting, and business experience. His role as an Analyst within the BioGenerator is to support due diligence and investment activity for new and existing portfolio companies.
Prior to joining the BioGenerator, Eric served as a consultant for the St. Louis based firm, MattsonJack (now Kantar Health). As part of his role, Eric participated in a variety of engagements with pharmaceutical and biotechnology companies in the field of drug discovery and commercialization. With a therapeutic focus in oncology, Eric’s primary experience was in the clinical and scientific assessment of new product entities in clinical development. His areas of expertise include thought leader insights, product and clinical pathway assessment, competitor profiling, portfolio prioritization decisions, sales forecasting, licensing due diligence, competitive intelligence and asset evaluation. The insight and knowledge provided by Eric assisted clients in prioritizing and driving decisions throughout the preclinical and clinical stages of development.
Eric earned his PhD in biochemistry from Washington University in St. Louis. Eric’s research experiences range from basic chemistry to molecular microbiology. His graduate work specifically investigated key virulence factors associated with urinary tract infections and bacterial pathogenesis. During this time, Eric also developed a key interest in the St. Louis entrepreneurial community and served a pivotal role in the development of the ongoing student-based organization, the BioEntrepreneurship Core. Eric received his bachelor’s degree in chemistry from the University of Arkansas.
Tahreem Shaikh joined BioGenerator in 2014 and brings nearly 18 years of mergers, acquisitions, and investment analysis experience. Before joining BioGenerator, Tahreem was at Peabody Energy, the world’s largest private sector coal company, in their Business Development Group. At Peabody, Tahreem worked on numerous national and international transactions including M&A, joint ventures, minority investments, and infrastructure development projects that helped expand the company’s footprint in Asia, Australia, and Africa.
Prior to Peabody Energy, Tahreem worked in Business Development & Licensing at Covidien Pharmaceuticals (now operating as Mallinckrodt Pharmaceuticals) where he executed numerous M&A and Licensing deals in the pharmaceutical and medical device sectors and provided financial and portfolio management support to the firm’s R&D and engineering teams. Prior to Mallinckrodt, Tahreem worked in the Finance & Acquisitions group of Charter Communications and reported to the CFO. At Charter he analyzed and managed numerous M&A and operational turnaround projects including approximately $1 billion in M&A and refinancing transactions. He began his career as an investment banking analyst with A.G. Edwards & Sons, Inc. (now part of Wells Fargo Capital Markets) where he focused on financial advisory engagements in the healthcare, technology, and high tech manufacturing industries.
Tahreem has a B.S. in Commerce from The McIntire School of Commerce at the University of Virginia and is a Level 3 Candidate for the Chartered Financial Analyst (CFA) designation.
Crystal has over 7 years of experience in biomedical research with expertise in the fields of cancer and bone biology. She received a B.S. in Molecular Biology from Bradley University, where she was involved in animal physiology research for 4 years. In 2011, Crystal received her Ph.D. in Molecular Cell Biology from Washington University in St. Louis. Crystal’s thesis research focused on analyzing the genetics of a mouse model for studying osteoclasts and the role of the ARF tumor suppressor in post-mitotic cells. During her academic career, she was also responsible for the critical review of scientific data spanning a broad spectrum of biomedical research.
Additionally, Crystal has held leadership positions for a consulting company that works with biotechnology start-ups. In this role, she focused on due diligence, market assessment, and interviewing key opinion leaders. Crystal joined BioGenerator as an investment analyst in 2013.
Rajesh (Raj) Devraj, Ph. D., has over 18 years of industry experience in drug discovery and development, business development and R&D strategy. He serves as a biotech executive, as a strategic/R&D advisor to pharma, biotech and VC firms, and serves on the Board of Directors of early stage biotechnology companies.
Raj is currently President & CEO of Euclises Pharmaceuticals Inc., a seed stage oncology focused drug discovery & development company that is developing small molecule inhibitors of an early inflammatory pathway that is up-regulated in a number of refractory cancers and is a primary driver of resistance to targeted therapy. Euclises’ clinical strategy utilizes a non-invasive biomarker to select patients who will most respond to therapy. Raj serves as a board member for a number of early stage drug discovery and development biotech companies including; Chairman of the Board for Antegrin Therapeutics LLC, Director & Board member of Mencuro Therapeutics Inc., Director & Board member of Tansna Therapeutics Inc., and Scientific Advisory Board member for Deciphera Pharmaceuticals LLC.
Raj was previously Senior Vice President, Deciphera Pharmaceuticals with responsibility for the company’s strategic planning and business development for its kinase cancer drug pipeline. Prior to that, he served as Senior Vice President, Head of Global Scientific & Portfolio Strategy at Jubilant Drug Discovery & Development responsible for managing and driving growth of the shared risk R&D portfolio and incubating internal discovery programs in oncology, CNS/pain and metabolic disorders. Raj spent 14 years in research leadership positions with Pfizer Global R&D and legacy Pharmacia and Searle companies, including being Senior Director, Global Platform Leader and Research Fellow. He has led multiple discovery & early development teams that have advanced eight candidates to clinical trials across autoimmune disorders, oncology, pain and metabolic disorders.
Raj has broad experience in the drug discovery and development process, including discovery research, preclinical development, IND preparation, design and conduct of early stage clinical trials, business development, negotiating and closing new collaborative agreements and program/asset deals. He received his Ph.D. degree in Medicinal Chemistry from Duquesne University, Pittsburgh PA and completed his National Cancer Institute Postdoctoral Fellowship at Purdue University, West Lafayette, IN.
Nandini Kishore, Ph.D., joined BioGenerator as an Entrepreneur in Residence in 2012.
Nandini has 25 years of experience in Drug Discovery, Development and Translational Medicine and has over fifty scientific publications. Currently, an Independent consultant, she maintains active interactions with Drug Discovery and Development teams both nationally and internationally in the Pharmaceutical and Biotechnology companies, and serves on the scientific advisory board of several start-up Life-Science companies globally.
Nandini has led drug discovery groups in the Inflammation research unit of Pfizer Global Research and Development. Her group was responsible for delivering new drug candidates from idea to clinical proof of concept (POC) including both small molecules and biologics. Additionally, she provided research leadership for a late stage drug candidate, a small molecule inhibitor of Janus family of kinases working closely with the Clinical and Regulatory teams. This drug candidate has completed global Phase III clinical trials for Rheumatoid Arthritis and has been submitted for Regulatory review by the FDA.
Nandini received her B.Sc and M.Sc from the University of Delhi, India and Ph.D from the University of Texas at Austin, in Biochemistry and Cell Biology. Following postdoctoral training in Washington University Medical School in St. Louis in the Departments of Biochemistry and Genetics, she joined Monsanto/Searle in 1986, as a Research Scientist. Monsanto/Searle merged with Pharmacia in 2000 and subsequently with Pfizer in 2003. Nandini has held positions of increasing responsibility during this transition and most recently served as an Executive Director in the Inflammation Research Division in St. Louis.
During her tenure in the Monsanto/Searle/ Pharmacia/Pfizer, Nandini made important contributions to multiple therapeutic areas including Infectious Diseases, Oncology, Allergy and Respiratory and Inflammation/Immunology. She has led many early and late stage projects, including large interdisciplinary project teams located in multiple geographic locations and has advanced drug candidates into the clinic. Examples include HIV protease inhibitors, metalloproteinase inhibitors for Oncology and kinase inhibitors for Rheumatoid Arthritis and other Autoimmune Diseases. She has several patents and has authored over 50 publications.
Randy is the Managing Partner and Co-Founder of Whetstone Associates and has extensive experience in Sales, Sales and Marketing Management, Product Development, New Business
Development and International Business. During his career in the medical device market place, he has been instrumental in the development and global launch of numerous products, which have had a major impact on the practice of Neurosurgery, Radiology and cardiology.
During the last six years Randy has been involved with two startup ventures. In early 2011, Randy joined Veran Medical Technologies, Inc. in St. Louis as Global GM Interventional Radiology and was responsible for the ig4 Electromagnetic Guidance technology, used in Interventional Radiology. Randy was responsible for managing the U.S. distribution of this product through GE Healthcare. In 2012 he presented this technology to the Chinese SFDA medical device panel, which resulted in obtaining full Chinese approval in 2013.
Prior to working with Veran, Randy served as V.P. of Sales and Marketing for InfraScan, Inc., a medical device startup in the traumatic brain injury triage market place. Randy organized the European launch of the InfraScanner in the United Kingdom in 2008.
Before joining InfraScan Randy was Director of Business and Market Development at Advanced Neuromodulation Systems, which was acquired by St. Jude Medical. He was instrumental in the early development, initial clinical trials and market development for the Libra DBS system, which is currently sold in Europe and Australia by St. Jude Medical.
As Group Director of Marketing at Sofamor Danek, he lead the product launch of StealthStation image guided surgery system, which has now become standard of care worldwide. He also served as V.P. Neurologic Technologies International where he was responsible for the global support of the Neurologic portfolio.
Randy spent eleven years with Codman and Shurtleff, Inc. as a field sales representative in Dallas and later as a member of field sales and marketing management. He joined the Storz Instrument Company and was instrumental in the integration of a Neurosurgery product line as Director of Marketing, and then led the sales organization as Director of Sales.
Randy has a Bachelor of Business Administration degree from Texas A&M. He is a Mentor with Innovate Venture Mentoring Services in St. Louis, and participates as a judge in the Hatchery program at Washington University. He has served on the Board of Memory Care Home Solutions, and the Glen Echo Golf Club.
Randy lives in St. Louis, Missouri with his wife Ellen and has 3 children and 3 grandchildren. He is an avid golfer and fly fisherman.
Alan MacInnes joined BioGenerator as an Entrepreneur in Residence (EIR) in May 2012. Since joining BioGenerator, Alan has successfully used his extensive pharmaceutical industry experience and growing business knowledge to create and grow several early stage bioscience companies that have received or are strong candidates for BioGenerator funding. Alan is currently Vice President of R&D with Tansna Therapeutics Inc., a drug discovery and development company that is developing novel oral anticonvulsant drugs for the treatment of refractory epilepsy. Alan has also successfully created two other new companies. He is CEO of Epigenetx, a drug discovery and development platform company focused on the development of epigenetic therapies for a wide spectrum of disease indications; and he is also CEO of YourBevCo LLC, a newly formed company focused on the beverage industry. Prior to joining the EIR program, Alan worked as a visiting professional with BioGenerator and successfully helped create a new BioGenerator company, Companion Pharma Inc. (CPI), an animal health product development company, for which Alan holds the role of corporate director and secretary of the board of directors.
Prior to joining BioGenerator, Alan spent 19 years in the pharmaceutical industry as a research and development scientist and project team leader with Pfizer Inc. both in the United Kingdom and the United States. During this period, Alan led projects and laboratories at all phases of the drug discovery and development continuum from new drug target validation to human phase 2 clinical proof of concept. At Pfizer, Alan participated in the identification of 10 drug candidates for human clinical development.
From 2007 – 2011 Alan was Associate Research Fellow and Research Project Leader in the Pfizer Indications Discovery Unit whose remit was to repurpose drug candidates within the Pfizer development portfolio for use in secondary disease indications. During this time Alan led two high-profile phase 2 clinical projects for acute coronary syndromes and dyslipidemia, reviewed and nominated numerous potential new drug opportunity ideas for diabetes and obesity as the therapeutic area expert and liaison, and built an obesity research laboratory capability from scratch.
In 2003 Alan transferred from the UK to the US with Pfizer following their acquisition of the Pharmacia Corporation and took a role as project and laboratory leader in the cardiovascular and metabolic diseases research group in St. Louis. During this period he led and contributed to projects targeting hypertension, thrombosis, diabetes and metabolic disease. He also served on new drug target identification/validation teams and cross functional licensing leadership teams.
From 1992 – 2003 Alan conducted and led research teams in the areas of thrombosis, atherosclerosis, vascular inflammation, hypertension and skeletal/cardiac metabolism within the cardiovascular research group at Pfizer in the UK.
During his career at Pfizer Alan led several collaborations with leading academic medical centers; he also performed due diligence for potential product licensing and strategic alliance opportunities. He has supervised, managed, and mentored numerous PhD, MSc, and BSc scientists.
Alan received his BSc (Hons) degree in Pharmacology from the University of Sunderland School of Pharmacy and has published more than 20 peer-reviewed articles during his career.
Dr. McCarter was the founder, President, and Chief Scientific Officer of Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease. The Company’s discoveries led to three products now in development in agrochemistry, veterinary therapeutics, and diagnostics. Divergence raised over $20 million in private equity and venture capital and achieved a successful exit in 2011 when it was acquired by Monsanto Company which has advanced its seed treatment to phase II in its technology pipeline. Dr. McCarter is currently an EIR with Monsanto Growth Ventures, an initiative by the company to invest in start-ups that have potential to create transformative tools and technologies for farmers. He is also an Adjunct Professor of Genetics at Washington University School of Medicine and an author of over 50 scientific publications. Dr. McCarter completed his medical and doctoral training at Washington University and graduated magna cum laude from Princeton University. He is the recipient of the Innovation Award from the Academy of Science of St. Louis and a Crown Fellow of the Aspen Institute
Dr. Olivo has twenty years experience in the biotechnology industry in key executive positions at both established and start-up companies. He is former Senior Medical Director of Quidel Corporation, a medical diagnostic device company in San Diego, CA. Prior to joining Quidel Dr Olivo was Senior Vice President of R&D at Diagnostic Hybrids, Inc. (Athens, OH) where he played a significant role in managing the company’s pipeline and intellectual property during the acquisition of the company by Quidel Corporation (San Diego, CA) in 2010.
Dr Olivo served as VP of R&D at St Louis start-up Apath, LLC and in 2000 became President and CSO. Dr. Olivo led a successful effort to license Apath's key hepatitis C virus patents to multiple diagnostic and pharmaceutical companies and led the development of a novel technology to develop antiviral drugs which was instrumental in the company’s receiving 18 federal grants totaling over $12M from 1999-2007.
While on the faculty at Washington University Dr. Olivo's ELVIS technology was licensed to Diagnostic Hybrids, Inc. a small medical diagnostics company in Ohio. Dr. Olivo worked closely with the company as it grew from 6 employees to 200 employees and $50M in sales when it was acquired by Quidel.
Dr. Olivo is a licensed physician and board-certified Internist. His medical degree was obtained from the University of Florida and his residency training (Internal Medicine) was performed at the University of Wisconsin where he was chief medical resident. Dr. Olivo performed his postdoctoral training in molecular virology at the National Institute of Allergy and Infectious Diseases at the NIH. He joined the faculty of Washington University in the Department of Medicine, Division of Infectious Diseases in 1989, and he retains an appointment as an adjunct member of the faculty in Molecular Microbiology. Dr Olivo is the inventor of multiple U.S. and foreign patents and has extensive knowledge of the application of genetically engineered cells to medical diagnostics. Currently Dr. Olivo is focusing his efforts on working with institutions in the greater St. Louis area to promote start up companies in the life sciences.
Dennis Schafer is an accomplished entrepreneur with more than 25 years' experience in organizing and managing new life science ventures, primarily in the Southeastern and Midwestern regions. In addition to his role as a Senior Entrepreneur in Residence at Biogenerator, he currently serves as President and CEO of Altheus Therapeutics, a Midwestern-based company pursuing mid-stage clinical development of a novel combination therapy for ulcerative colitis.
Dennis has played leadership roles in twelve start-ups, serving as CEO in several of them, accessing technologies from multiple universities as well as corporate sources; raising start-up capital from more than a dozen institutional venture funds; and forming corporate partnerships with both major and mid-major pharmaceutical companies. Companies in his portfolio include BioCryst Pharmaceuticals, Zynaxis (acquired Secretech), Avant Immunotherapeutics (acquired Megan Health), Coley Pharmaceuticals, Aderis Pharmaceuticals, Somatacor, Curry Pharmaceuticals, FASgen, and Altheus Therapeutics. Collectively, these companies have launched a new drug for Parkinson’s Disease, advanced several other human products into clinical testing, and launched two animal vaccines. Four of the companies have become publicly traded, and four have been acquired by larger biotech or pharma companies.
Dennis received his BA with distinction from the University of Nebraska, and earned an MA in English and an MBA from the University of Virginia, where he also served for two years as a member of the research faculty in business strategy at the Darden Graduate School of Business.